Answer
Leniolisib phosphate (Joenja) is not recommended for patients with moderate to severe hepatic impairment; the effect of hepatic impairment on leniolisib pharmacokinetics has not been studied.
Sources for this answer
- Joenja 70 mg Film-coated tabletsPharming Technologies B.V. · emc · SmPC §4.2 Posology and method of administration · Version 2Document updated
Sources checked